Log in

Globus Medical Stock Price, News & Analysis (NYSE:GMED)

$50.46
+1.01 (+2.04 %)
(As of 10/14/2019 02:19 AM ET)
Today's Range
$49.21
Now: $50.46
$51.14
50-Day Range
$48.80
MA: $50.75
$52.16
52-Week Range
$38.01
Now: $50.46
$57.83
Volume328,955 shs
Average Volume372,628 shs
Market Capitalization$5.00 billion
P/E Ratio30.22
Dividend YieldN/A
Beta0.97
Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP37957720
Phone610-930-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$712.97 million
Cash Flow$2.20 per share
Book Value$12.03 per share

Profitability

Net Income$156.47 million

Miscellaneous

Employees1,800
Market Cap$5.00 billion
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.


Globus Medical (NYSE:GMED) Frequently Asked Questions

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

How were Globus Medical's earnings last quarter?

Globus Medical Inc (NYSE:GMED) released its earnings results on Thursday, August, 1st. The medical device company reported $0.41 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $0.41. The medical device company earned $150.55 million during the quarter, compared to analyst estimates of $184.93 million. Globus Medical had a net margin of 19.30% and a return on equity of 13.29%. The company's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.44 earnings per share. View Globus Medical's Earnings History.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Globus Medical.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of $1.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.72. The company issued revenue guidance of $770-775 million, compared to the consensus revenue estimate of $768.63 million.

What price target have analysts set for GMED?

9 Wall Street analysts have issued 1-year price targets for Globus Medical's shares. Their forecasts range from $45.00 to $65.00. On average, they expect Globus Medical's stock price to reach $56.67 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View Analyst Price Targets for Globus Medical.

What is the consensus analysts' recommendation for Globus Medical?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.

What are Wall Street analysts saying about Globus Medical stock?

Here are some recent quotes from research analysts about Globus Medical stock:
  • 1. According to Zacks Investment Research, "Globus Medical posted a mixed second-quarter performance with earnings meeting the Zacks Consensus Estimate while revenues beating the mark. Globus Medical witnessed strength in the United States and the international regions as well as in the Musculoskeletal solutions and Enabling Technologies segments. The company has delivered strong top-line numbers for its Spine arm. Implant pull-through from ExcelsiusGPS placements and back-to-back record sales force recruiting years were the primary growth drivers. Overall, the stock has outperformed its industry in the past three months. However, the pricing scenario is persistently tough for Globus Medical." (8/6/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019)

Has Globus Medical been receiving favorable news coverage?

News headlines about GMED stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Globus Medical earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Globus Medical.

Are investors shorting Globus Medical?

Globus Medical saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 2,200,000 shares, a decrease of 23.1% from the August 15th total of 2,860,000 shares. Based on an average daily volume of 591,600 shares, the short-interest ratio is currently 3.7 days. Approximately 2.9% of the shares of the company are short sold. View Globus Medical's Current Options Chain.

Who are some of Globus Medical's key competitors?

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include AbbVie (ABBV), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Alibaba Group (BABA), Novartis (NVS), Intuitive Surgical (ISRG), Bausch Health Companies (BHC), Johnson & Johnson (JNJ), Intel (INTC) and NVIDIA (NVDA).

Who are Globus Medical's key executives?

Globus Medical's management team includes the folowing people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
  • Mr. David M. Demski, CEO & Director (Age 61)
  • Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
  • Mr. David D. Davidar, Co-Founder & Director (Age 53)
  • Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Gofen & Glossberg LLC IL (0.07%), Pacer Advisors Inc. (0.03%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.

Which major investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc. and Gofen & Glossberg LLC IL. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical.

Which major investors are buying Globus Medical stock?

GMED stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Globus Medical.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $50.46.

How big of a company is Globus Medical?

Globus Medical has a market capitalization of $5.00 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical.

What is Globus Medical's official website?

The official website for Globus Medical is http://www.globusmedical.com/.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]


MarketBeat Community Rating for Globus Medical (NYSE GMED)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  441 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  814
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel